Valuation: Alaunos Therapeutics, Inc.

Market Cap 4.63M 3.99M 3.75M 3.41M 6.42M 442M 6.51M 43.92M 17.21M 222M 17.37M 16.99M 737M P/E 2024
-0.65x
P/E 2025 -1.47x
Enterprise Value 3.24M 2.8M 2.63M 2.39M 4.5M 310M 4.56M 30.77M 12.06M 155M 12.17M 11.91M 516M EV / Sales 2024
195,938,500x
EV / Sales 2025 1,164,761,400x
Free-Float
84.09%
Yield 2024 *
-
Yield 2025 -
1 day-1.04%
1 week-3.54%
Current month+1.60%
1 month-6.83%
3 months-22.67%
6 months-25.97%
Current year-40.87%
1 week 1.85
Extreme 1.8503
2.05
1 month 1.81
Extreme 1.81
2.19
Current year 1.81
Extreme 1.81
4.04
1 year 1.67
Extreme 1.67
4.59
3 years 1.31
Extreme 1.3137
32.85
5 years 1.31
Extreme 1.3137
601.5
10 years 1.31
Extreme 1.3137
1,182
Manager TitleAgeSince
Chief Executive Officer 63 2025-07-01
Director of Finance/CFO 41 2025-02-21
Director TitleAgeSince
Director/Board Member 57 2020-12-15
Chairman 63 2023-09-21
Director/Board Member 72 2021-02-04
Date Insider Type Main position Quantity % Market Cap.
8/6/26 Free

Chief Executive Officer

4,363 0.1787%
7/23/26 Free

Director

8,138 0.3332%
7/23/26 Free

Chief Executive Officer

4,568 0.1870%
Change 5-day change 1-year change 3-year change Capi.($)
-1.04%-3.54%-15.11%-90.29% 4.67M
+4.80%+3.44%+70.64%+109.32% 70.07B
+17.12%+11.50%+54.42%+87.30% 52.87B
+3.70%-4.77%+0.41%+484.07% 27.02B
+4.64%+5.00%+55.74%+20.55% 23.61B
-1.60%-1.29%-19.31%-19.10% 23.38B
-6.00%+6.02%+244.39%+430.80% 19.43B
+3.80%+5.62%+40.50%-15.26% 18.75B
+3.64%+2.37%+21.08%+555.76% 15.85B
+2.11%-1.21%+36.57%+149.14% 12.7B
Average +3.10%-0.07%+48.93%+171.23% 26.37B
Weighted average by Cap. +5.50%+2.25%+56.92%+167.56%

Financials

2024 2025
Net sales 0.01 0.01 0.01 0.01 0.01 0.96 0.01 0.09 0.04 0.48 0.04 0.04 1.59 0 0 0 0 0.01 0.48 0.01 0.05 0.02 0.24 0.02 0.02 0.8
Net income -4.68M -4.04M -3.79M -3.45M -6.49M -447M -6.58M -44.42M -17.41M -224M -17.57M -17.19M -746M -4.18M -3.61M -3.38M -3.08M -5.79M -399M -5.87M -39.65M -15.54M -200M -15.68M -15.34M -665M
Net Debt -1.09M -942K -884K -805K -1.51M -104M -1.53M -10.36M -4.06M -52.26M -4.1M -4.01M -174M -1.38M -1.2M -1.12M -1.02M -1.92M -132M -1.95M -13.15M -5.15M -66.34M -5.2M -5.09M -221M
Logo Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.
Employees
1
Date Price Change Volume
26-08-17 US$1.910 -1.04% 17,664
26-08-14 US$1.930 -3.02% 11,715
26-08-13 US$1.990 -0.50% 7,774
26-08-12 US$2.000 +1.52% 7,203
26-08-11 US$1.970 -0.51% 5,224

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TCRT Stock